The primary objective of this open-label, flexible dose study is to assess the safety and efficacy of pramipexole over a 24-week period in children and adolescents (age 6-17 years inclusive) diagnosed with Tourette Syndrome according to DSM-IV criteria and who have completed either Study 248.641 or 248.644. The safety of pramipexole will be evaluated collectively for the incidence of adverse events, the proportion of withdrawals due to drug related adverse events, and the assessment of the following scales: • Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS); • Child Behavior Checklist (CBCL) ; • DuPaul Attention-Deficit / Hyperactivity Disorder (ADHD) Rating Scale-IV; • Child Depression Inventory-Short Version CDI-S; • Multidimensional Anxiety Scale for Children (MASC).